Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Eruptive Disseminated Superficial Porokeratosis and Multiple Dermatofibromas in a Patient with Systemic Lupus Erythematosus under Belimumab Therapy: A Case Report.

Created on 11 Jul 2026

Authors

Mai Endo, Ryuto Mukaiyama, Toshiyuki Yamamoto

Published in

Case reports in dermatology. Volume 18. Issue 1. Pages 405-410. Epub May 23, 2026.

Abstract

There have been several reports on non-actinic disseminated superficial porokeratosis in association with autoimmune diseases, malignant disorders, or immunosuppressive/immunomodulatory therapies.
A 36-year-old female with systemic lupus erythematosus developed eruptive disseminated superficial porokeratosis on the lower legs, which appeared and increased in number after belimumab therapy was started. Physical examination showed 40 brownish superficial round plaques with slightly elevated borders on the bilateral lower legs. Histopathology revealed a narrow stack of parakeratotic corneocytes (cornoid lamella), compatible with porokeratosis. In addition, a total of 6 brownish, firm dermal nodules were observed on the thigh and lower back, which appeared a few years after the development of porokeratosis. Histopathological examination revealed dermatofibroma.
To the best of our knowledge, there have been no reports of multiple porokeratosis under belimumab therapy. Biologic therapy may be associated with epigenetic changes in the candidate gene variation.

PMID:
42434588
Bibliographic data and abstract were imported from PubMed on 11 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement